{'fraction_non_alphanumeric': 0.0665024630541872, 'fraction_numerical': 0.10385878489326765, 'mean_word_length': 4.589449541284404, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The landscape of palliative systemic therapy and overall survival of 2,063 advanced breast cancer patients in the China National Cancer Center.

e12583 Background: Despite novel therapeutic options evolved rapidly, advanced breast cancer (ABC) remains an incurable disease with a median overall survival (OS) of 24-30 months. However, real-world data on the treatment and outcome of ABC in routine practice was rare, especially in Chinese cohort. Methods: We summarized the clinicopathological characteristics, therapeutic regimens and survival outcome of 2063 females with ABC who were hospitalized between January 2003 and December 2013 from the Database in China National Cancer Center. Results: The median OS of enrolled population was 42.6 months (95% CI 39.6 to 45.5). Significantly prolonged OS was observed since 2011 ( P= 0.041), with a median OS of 41.0 months (95% CI 37.5 to 44.4) in patients diagnosed with ABC in 2003-2010 and 44.6 months (95% CI 37.9 to 51.2) in 2011-2013, respectively. Between these two periods, Luminal-like, HER2-positive, and Triple-negative patients had an improved median OS of 45.9 to 56.2 months ( P= 0.001), 38.3 to 43.1 months ( P= 0.414), and 28.6 to 28.7 months ( P= 0.364), respectively. As for the analysis of therapeutic mode alteration, the proportion of multidisciplinary care for recurrent disease raised significantly over the years (χ2= 8.2, P= 0.004), from 39.6% in 2003-2010 to 47.7% in 2011-2013. In Luminal-like patients, the application of endocrine therapy increased significantly from 64.4% in 2003-2010 to 77.6% in 2011-2013 during the palliative systemic therapy (χ2= 17.7, P < 0.001). Among HER2-positive patients, significantly increased application of HER2-targeted therapy were observed in both adjuvant therapy (χ2= 4.7, P= 0.030) and palliative therapy (χ2= 10.3, P= 0.001) between these two periods. For patients receiving the first-line chemotherapy, the use of maintenance treatment ascended dramatically from 37.1% in 2003-2010 to 58.8% in 2011-2013 (χ2= 50.5, P < 0.001). The percentage of participating clinical trials was 14.3%, slightly increased in 2011-2013, when compared with the proportion of 11.6% in 2003-2010 (χ2= 2.0, P= 0.160). Conclusions: Real-world data revealed that significantly prolonged OS in China was achieved since 2011 due to the increased use of multidisciplinary care, endocrine therapy, HER2-targeted therapy and maintenance treatment.